Haitao Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Haitao Xu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alana Christie
O’Donnell-SPH- Biostatistics Shared Resource, The University of Texas Southwestern Medical Center, Dallas, USA
1 shared publication Alexander Parker
Office of Research Affairs, College of Medicine , Jacksonville, FL
1 shared publication- Bradley C. Leibovich
Department of Urology, Mayo Clinic, Rochester, MN 55905, USA
1 shared publication Colleen T Ball
Office of Research Affairs, College of Medicine , Jacksonville, FL
1 shared publicationDavid D Thiel
Department of Urology, Mayo Clinic , Jacksonville, FL
1 shared publication- David Kim
Department of Pathology, University of Texas Southwestern Medical Center , Dallas, TX
1 shared publication
Latest Publications
- 11 March 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (7) , 1387-1400
Determinants of late metastases in renal cell carcinoma
Background: The mechanisms underlying metastatic latency in renal cell carcinoma (RCC) remain poorly understood. Methods: This study evaluated 2 large independent cohorts for differences in tumor biology between patients who developed metastases early (≤1 year after nephrectomy) and those with late onset (>3 years). Results: In the discovery cohort (n = 161), late metastatic RCC was associated with clear cell histology (88.9% vs 78.7%), lower pathological stage (pT1-2; 40.3% vs 18.0%), and favorable histopathological features including low grade (40.0% vs 2.3%), less sarcomatoid (5.6% vs 21.8%), and reduced necrosis (37.7% vs 78.3%; all P < .02). Late metastatic RCC tumors exhibited increased angiogenesis (63.5% vs 19.4%) and reduced inflammation (78.8% vs 50.0%; all P < .02) profiles. Genomic driver analyses revealed comparable rates of PBRM1 and SETD2 loss in late and early metastatic RCC, while BAP1 loss was significantly less common in late metastatic RCC (7.5% vs 27.1%; P < .02). In multivariable models, BAP1/PBRM1/SETD2 status and tumor necrosis emerged as key discriminators of late metastatic RCCs. These findings were confirmed in the second cohort (n = 307). Late metastatic RCC was enriched for fatty acid oxidation and angiogenesis pathways, supporting a less aggressive phenotype. This was further evidenced by a lower engraftment rate in murine models (0% vs 36.5%; P < .001) and significantly longer overall survival from the time of metastasis (median survival doubled, P < .001). Interestingly, late metastatic RCC shared genomic and phenotypic features with RCC that metastasizes to the pancreas, suggesting a common underlying biology influencing both metastatic latency and pancreatic tropism. Conclusions: Overall, these findings advocate for recognition of late metastatic RCC because of its distinct biology and improved prognosis.
- 11 March 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (7) , 1387-1400
Determinants of late metastases in renal cell carcinoma
Background: The mechanisms underlying metastatic latency in renal cell carcinoma (RCC) remain poorly understood. Methods: This study evaluated 2 large independent cohorts for differences in tumor biology between patients who developed metastases early (≤1 year after nephrectomy) and those with late onset (>3 years). Results: In the discovery cohort (n = 161), late metastatic RCC was associated with clear cell histology (88.9% vs 78.7%), lower pathological stage (pT1-2; 40.3% vs 18.0%), and favorable histopathological features including low grade (40.0% vs 2.3%), less sarcomatoid (5.6% vs 21.8%), and reduced necrosis (37.7% vs 78.3%; all P < .02). Late metastatic RCC tumors exhibited increased angiogenesis (63.5% vs 19.4%) and reduced inflammation (78.8% vs 50.0%; all P < .02) profiles. Genomic driver analyses revealed comparable rates of PBRM1 and SETD2 loss in late and early metastatic RCC, while BAP1 loss was significantly less common in late metastatic RCC (7.5% vs 27.1%; P < .02). In multivariable models, BAP1/PBRM1/SETD2 status and tumor necrosis emerged as key discriminators of late metastatic RCCs. These findings were confirmed in the second cohort (n = 307). Late metastatic RCC was enriched for fatty acid oxidation and angiogenesis pathways, supporting a less aggressive phenotype. This was further evidenced by a lower engraftment rate in murine models (0% vs 36.5%; P < .001) and significantly longer overall survival from the time of metastasis (median survival doubled, P < .001). Interestingly, late metastatic RCC shared genomic and phenotypic features with RCC that metastasizes to the pancreas, suggesting a common underlying biology influencing both metastatic latency and pancreatic tropism. Conclusions: Overall, these findings advocate for recognition of late metastatic RCC because of its distinct biology and improved prognosis.